Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04294667 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus
A Phase 3 study of Systemic Lupus Erythematosus, sponsored by UCB Biopharma SRL.
- Completed
- Registry status
- Phase 3
- Development phase
- 321
- Enrollment target
- 20
- Study locations
NCT04294667 is a Phase 3 study of Systemic Lupus Erythematosus that has completed, run by UCB Biopharma SRL. The registered enrollment target is 321 participants, below the 377-participant average among 99 other Systemic Lupus Erythematosus trials with a reported enrollment target (15% lower). The trial reports 20 study locations across 7 states.
The verdict
NCT04294667, a Phase 3 study of Systemic Lupus Erythematosus, has completed, sponsored by UCB Biopharma SRL.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 321 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the ability of dapirolizumab pegol (DZP) as an add-on treatment to standard of care (SOC) medication to achieve clinically relevant long term improvement of moderate to severe disease activity.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG DZP
Study Locations (20)
California
- Sl0043 50383 - Beverly Hills
- Sl0043 50257 - La Jolla
- Sl0043 50275 - La Palma
- Sl0043 50378 - Loma Linda
- Sl0043 50258 - Los Angeles
- Sl0043 50340 - Orange
- Sl0043 50331 - Poway
- Sl0043 50377 - San Diego
- Sl0043 50316 - San Leandro
Florida
- Sl0043 50239 - Brandon
- Sl0043 50362 - Gainesville
- Sl0043 50122 - Miami
- Sl0043 50059 - Ormond Beach
- Sl0043 50324 - Plantation
Arizona
- Sl0043 50052 - Phoenix
- Sl0043 50328 - Tucson
Alabama
- Sl0043 50140 - Birmingham
Colorado
- Sl0043 50339 - Denver
Connecticut
- Sl0043 50367 - New Haven
District of Columbia
- Sl0043 50341 - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 321 participants |
| Start Date | 2020-08-12 |
| Est. Completion | 2024-06-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04294667
The ClinicalTrials.gov registry entry for NCT04294667 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 321 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 377-participant average among 99 other Systemic Lupus Erythematosus trials with a reported enrollment target (15% lower). The listed sponsor is UCB Biopharma SRL, which has 82 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Systemic Lupus Erythematosus appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT04294667 reports 20 study locations spanning 7 distinct geographic areas - top geographies include California, Florida, Arizona.
Frequently Asked Questions
What is clinical trial NCT04294667 about?
NCT04294667 is a clinical study titled "A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus". The purpose of this study is to evaluate the ability of dapirolizumab pegol (DZP) as an add-on treatment to standard of care (SOC) medication to achieve clinically relevant long term improvement of moderate to severe disease activity.
What is the current status of trial NCT04294667?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 321 participants. The study started on 2020-08-12. Estimated completion is 2024-06-04.
What conditions does trial NCT04294667 study?
This clinical trial studies the following conditions: Systemic Lupus Erythematosus.
What interventions are being tested in trial NCT04294667?
The interventions under investigation include: Placebo (OTHER), DZP (DRUG).
Who is sponsoring clinical trial NCT04294667?
This trial is sponsored by UCB Biopharma SRL, which has 82 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04294667 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Systemic Lupus Erythematosus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus
RECRUITING · Phase 3
-
Effects of Stopping Hydroxychloroquine in Elderly Lupus Disease
RECRUITING · Phase 3
-
An Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric Participants
RECRUITING · Phase 3
-
Phase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIRIUS-SLE Extension).
RECRUITING · Phase 3
-
A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus
RECRUITING · Phase 3
-
A Study to Evaluate Effectiveness and Safety of Deucravacitinib (BMS-986165) Compared With Placebo in Participants With Active Systemic Lupus Erythematosus
ACTIVE NOT RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.